Testosterone Cypionate for Sarcopenia: Off-Label Risks, Benefits, and Clinical Evidence

What Sarcopenia Is and Why Testosterone Enters the Conversation

Sarcopenia is the progressive loss of skeletal muscle mass, strength, and physical performance that accelerates after age 60. The European Working Group on Sarcopenia in Older People (EWGSOP2) published revised diagnostic criteria in 2019, defining probable sarcopenia as low grip strength (<27 kg in men, <16 kg in women) confirmed by reduced muscle quantity on DXA or BIA [1]. The condition is not merely cosmetic. Sarcopenic older adults face a two- to five-fold increased risk of falls, disability, and mortality compared to age-matched controls [2].

Testosterone enters this picture because serum levels decline approximately 1 to 2% per year after age 30, and that decline correlates with reduced muscle protein synthesis [3]. Testosterone cypionate, a long-acting injectable ester, is FDA-approved only for classical male hypogonadism caused by testicular, pituitary, or hypothalamic disorders [4]. Its use in sarcopenia is entirely off-label. The distinction matters: prescribers carry the burden of informed consent, and patients should understand the evidence does not meet the same regulatory threshold as an approved indication. Still, the biological rationale is straightforward. Testosterone activates androgen receptors in skeletal muscle, stimulates satellite cell proliferation, and suppresses myostatin signaling. The question is whether these mechanisms produce clinically meaningful improvements in older adults already losing muscle.

The Evidence for Lean Mass Gains

Testosterone therapy consistently increases lean body mass in older men with low or low-normal testosterone. That finding is reproducible. A 2020 systematic review and meta-analysis of 52 randomized controlled trials (N=5,067) published in The Journal of Clinical Endocrinology & Metabolism found that testosterone treatment increased lean mass by a weighted mean of 1.58 kg (95% CI: 1.20 to 1.97) compared to placebo [5]. The effect was dose-dependent. Trials using intramuscular formulations (including testosterone cypionate and enanthate at doses of 100 to 200 mg weekly or biweekly) produced larger gains than transdermal preparations.

The TTrials, a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older with serum testosterone <275 ng/dL, reported that one year of testosterone gel increased lean mass by 0.9 kg more than placebo while simultaneously reducing fat mass by 0.7 kg [6]. These body composition shifts were statistically significant but modest.

A critical distinction: gaining lean mass does not automatically translate to gaining strength or function. The relationship between muscle quantity and muscle quality weakens with age. Some trials show lean mass increases without proportional strength gains, a pattern the EWGSOP2 consensus specifically warns against over-interpreting [1]. Dr. Alfonso Cruz-Jentoft, lead author of the EWGSOP2 definition, has stated: "Muscle mass alone is a poor proxy for sarcopenia severity. Clinicians must measure function, not just size" [1].

Does Testosterone Improve Physical Function in Sarcopenic Patients?

The most direct evidence comes from the TTrials Physical Function Trial, which enrolled 170 men aged 65 and older who had objective mobility limitations (Short Physical Performance Battery score <10) and low testosterone [7]. After 12 months of testosterone gel titrated to mid-normal levels (target: 500 to 800 ng/dL), the testosterone group improved their 6-minute walk distance by 14.7 meters more than placebo. That number did not reach the pre-specified 50-meter minimal clinically important difference.

Put plainly: the improvement was real but small. The TEAAM trial (Testosterone's Effects on Atherosclerosis Progression in Aging Men, N=308) found similar results over 36 months. Testosterone enanthate at 7.5 g of 1% gel daily improved lean mass and reduced fat mass but did not significantly improve leg press strength or physical performance composite scores compared to placebo [8].

Not every trial has been disappointing. A 2019 RCT by Storer et al. published in JAMA Internal Medicine (N=170) tested testosterone enanthate 100 mg weekly in men aged 65 and older with mobility limitations and found significant improvements in stair-climbing power, loaded and unloaded walking speed, and leg press strength at 6 months [9]. The key difference: this trial used a higher, fixed intramuscular dose rather than titrated gel, and it enrolled men with more severe baseline limitations. The dose and route may matter more than commonly acknowledged.

Cardiovascular Risks: What TRAVERSE Revealed

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men) is the largest cardiovascular safety trial of testosterone therapy to date [10]. Published in The New England Journal of Medicine in 2023, it randomized 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease to daily transdermal testosterone gel or placebo.

The primary composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group over a median of 33 months (HR 0.96 to 95% CI: 0.78 to 1.17) [10]. That met the non-inferiority threshold. Testosterone was not statistically worse than placebo for MACE.

But secondary outcomes raised flags. The testosterone group had higher rates of atrial fibrillation (3.5% vs. 2.4%), acute kidney injury (2.3% vs. 1.5%), and pulmonary embolism (0.9% vs. 0.5%) [10]. Polycythemia (hematocrit >54%) occurred in 3.2% of testosterone-treated men versus 0.4% on placebo. The FDA updated testosterone product labeling in 2024 to reflect these findings, adding warnings about atrial fibrillation, venous thromboembolism, and polycythemia [4].

For sarcopenia patients, who are typically older and often carry cardiovascular comorbidities, these secondary signals deserve serious weight. A 75-year-old man with atrial fibrillation and sarcopenia is a different risk-benefit calculation than a 55-year-old with isolated low testosterone.

What the Guidelines Actually Say

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism provides the most authoritative position [11]. The guideline recommends testosterone therapy for men with "classical hypogonadism" (defined by symptoms plus consistently low morning testosterone with a confirmed cause) at Grade 1, strong recommendation. It explicitly recommends against prescribing testosterone to men with age-related decline in testosterone who do not meet criteria for classical hypogonadism (Grade 2, weak recommendation based on low-quality evidence).

Dr. Shalender Bhasin, the guideline panel chair, stated in the accompanying commentary: "There is insufficient evidence to recommend testosterone therapy for the treatment of sarcopenia, frailty, or age-related functional decline as stand-alone indications" [11].

The American Geriatrics Society and the International Conference on Sarcopenia and Frailty Research (ICSFR) both position resistance exercise as the primary intervention, with pharmacotherapy considered only when exercise alone is insufficient and when a treatable hormonal deficiency coexists [12]. The ICSFR 2022 guideline assigns a conditional recommendation (GRADE: low certainty) to testosterone supplementation in sarcopenic men with documented hypogonadism.

This creates a practical gray zone. A man with sarcopenia and a morning total testosterone of 220 ng/dL has overlapping indications. Treating his hypogonadism is guideline-concordant; the sarcopenia benefit is a secondary effect. A man with sarcopenia and a testosterone of 380 ng/dL sits outside guideline recommendations, even if his clinician suspects hormonal contribution.

Dosing and Monitoring for Off-Label Use

When clinicians prescribe testosterone cypionate off-label for sarcopenia in hypogonadal men, the dosing mirrors standard TRT protocols. Typical starting doses range from 100 to 200 mg intramuscularly every 7 to 14 days [11]. The Endocrine Society recommends targeting mid-normal serum testosterone levels (450 to 600 ng/dL measured at trough, 7 days post-injection) rather than pushing to the upper limit.

Monitoring is non-negotiable. Baseline labs should include total testosterone (drawn before 10 AM, fasted), hematocrit, PSA, lipid panel, hepatic function, and a metabolic panel [11]. Follow-up labs at 3 months, 6 months, and then every 6 to 12 months are standard. Hematocrit above 54% requires dose reduction or phlebotomy. PSA velocity above 1.4 ng/mL per year warrants urologic referral.

For sarcopenia-specific monitoring, clinicians should track grip strength (using a calibrated dynamometer), gait speed (4-meter walk), and DXA-derived appendicular lean mass index at baseline and 6- to 12-month intervals [1]. Without these functional assessments, there is no way to determine whether the testosterone is producing a sarcopenia-relevant benefit or merely shifting body composition without functional gain.

Subcutaneous injection of testosterone cypionate at 50 to 80 mg twice weekly has gained clinical traction as an alternative route, producing more stable serum levels with lower hematocrit elevations in observational data [13]. No large RCTs have directly compared subcutaneous and intramuscular testosterone cypionate for sarcopenia outcomes.

Resistance Exercise: The Comparison That Cannot Be Ignored

Any discussion of testosterone for sarcopenia that omits exercise is incomplete. A 2021 Cochrane review of progressive resistance training (PRT) in older adults (44 trials, N=3,713) found that PRT improved leg press strength by a standardized mean difference of 1.49 (95% CI: 1.05 to 1.93) and increased gait speed by 0.11 m/s (95% CI: 0.03 to 0.19) [14]. These effect sizes exceed what testosterone monotherapy achieves in most trials.

The combination of testosterone plus resistance exercise has been studied less rigorously. A 2018 RCT by Gharahdaghi et al. found that testosterone enanthate (125 mg weekly) combined with resistance training in men aged 65 to 75 produced greater gains in lean mass (2.1 kg vs. 0.9 kg) and leg press 1RM (23% vs. 14%) compared to exercise plus placebo over 12 weeks [15]. The additive benefit was real but raises the question of whether the testosterone component justifies its risks when exercise alone produces significant improvements.

The ICSFR guideline positions exercise as first-line therapy with Grade A evidence and suggests that pharmacotherapy be reserved for patients who cannot exercise adequately or who have documented hormonal deficiency [12]. A bed-bound patient with a hip fracture, hypogonadism, and severe sarcopenia represents the clinical scenario where off-label testosterone has the strongest rationale.

Who Might Reasonably Be Considered for Off-Label Testosterone

The ideal candidate is narrow. Based on the available evidence, testosterone cypionate for sarcopenia is most defensible in men who meet all of the following criteria: confirmed sarcopenia by EWGSOP2 criteria (low grip strength plus low muscle mass), documented hypogonadism (total testosterone <300 ng/dL on two morning samples), failure to improve with 12 or more weeks of supervised resistance exercise, absence of contraindications (untreated polycythemia, prostate cancer, severe sleep apnea, heart failure NYHA Class III/IV), and willingness to undergo regular monitoring [11][12].

This is not a broad population. The overlap between "sarcopenic" and "hypogonadal with no contraindications and exercise-refractory" describes a minority of older men with muscle wasting. For the majority, resistance exercise, adequate protein intake (1.0 to 1.2 g/kg/day per ESPEN guidelines [16]), and vitamin D repletion remain the foundation.

Women with sarcopenia are excluded from this discussion almost entirely. Testosterone cypionate has minimal trial data in older women for sarcopenia, and the virilizing side effects at doses that increase lean mass limit its clinical application in this population.